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The role of radical prostatectomy in high-risk prostate 
cancer
Byung Ha Chung 
Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea 
Because of the increase in prostate cancer patients, urologists can detect more clinically localized prostate cancer in patients before 
the disease has progressed to advanced stages. Nevertheless, some patients are still diagnosed with high-risk prostate cancer. Even 
though several treatment options are available for high-risk prostate cancer patients, including radical prostatectomy, radiotherapy, 
and hormone therapy, used alone or in combination, the recurrence rate is high regardless of the type of treatment. Nevertheless, in 
the experience of many urologists, a substantial proportion of high-risk prostate cancer patients are cured by local definite therapy or 
multimodality treatment. Thus, several treatment combinations have been attempted as treatments in these patients. Among them, 
radical prostatectomy is regarded as the first step in high-risk prostate cancer patients, on a selective basis. In some high-risk prostate 
cancer patients, surgery is a one-step modality in treatment and has an excellent oncological prognosis. However, because of the lack of 
evidence and well-controlled comparative prospective studies, the best course of treatment can be unclear, and oncological outcomes 
often appear heterogeneous. We therefore review the current literature on clinical outcomes in high-risk prostate cancer.
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INTRODUCTION
Prostate cancer is the most common cancer among men in 
Western countries [1-3]. In Asia, a recent rapid increase in 
the incidence and detection of prostate cancer has been ob-
served. Environmental elements, such as increased average 
life expectancy, the change to Western dietary habits, and the 
medical development of laboratory diagnosis and prostate-
specific antigen (PSA) screening campaigns [4] are believed 
to be causal factors in the increased incidence of prostate 
cancer. Because of PSA screening, urologists can detect clini-
cally localized prostate cancer in patients before the disease 
has progressed to advanced stages. Because many indolent 
cancers can be detected, prostate cancer mortality rates de-
clined significantly between 1990 and 2005 [5]. Nevertheless, 
some prostate cancer patients still die because the disease 
progresses [6]. Prostate cancer patients who have a higher 
likelihood of disease progression despite definite therapy, 
including radical prostatectomy (RP) and radiotherapy (RT), 
are classified by urologists as high-risk prostate cancer pa-
tients [7], and they are acknowledged to be at a higher risk for 
prostate-related death [8,9]. 
 In high-risk prostate cancer patients, the best course of 
treatment is often unclear, and the oncological outcomes ap-
pear heterogeneous. Even though several treatment options, 
including RP, RT, and hormone therapy (HT) alone or in com-
bination, are available for high-risk prostate cancer patients, 
the recurrence rate is high regardless of the type of treatment 
[10,11]. Despite the lack of high-level evidence of treatment 
benefits for these patients, the high-risk of disease progres-
sion and death from the disease may result in making active 
treatment, including RP, a preferred option. The aim of this 




article is to define high-risk prostate cancer and to review the 
various outcomes after RP.
DEFINITION OF HIGH-RISK PROSTATE 
CANCER
The definition of high-risk prostate cancer varies according 
to clinical stratification systems (Table 1) [1,2,12-14]. Using 
these classification systems, urologists can predict the bio-
chemical recurrence (BCR) after definitive therapy. The most 
commonly used model was developed by D’Amico et al. [12]. 
This model is based on the preoperative PSA, the preopera-
tive Gleason score, and the clinical stage of the disease. High-
risk prostate cancer was defined as preoperative PSA > 20 ng/
mL and/or preoperative Gleason score of 8–10 and/or clinical 
stage ≥ T2c. In The National Comprehensive Cancer Network 
[13] and European Association of Urology [1], the definition 
of high-risk prostate cancer varied in D’Amico et al. as preop-
erative PSA > 20 ng/mL and/or preoperative Gleason score of 
8–10 and/or clinical stage ≥ T3a. In addition, other investiga-
tors have developed definitions of high-risk prostate cancer, 
which differ slightly. In other words, the exact definition of 
high-risk prostate cancer is unclear and a consensus has not 
yet been reached. 
 This situation has brought about difficulties in the compar-
ison of oncological outcomes of high-risk prostate cancer, the 
clinical assessment of risk classification, etc. Moreover, there 
is a certain limitation in prostate cancer risk classification 
using the three basic parameters: the preoperative PSA, the 
preoperative Gleason score, and the clinical stage of the dis-
ease. In the case of PSA level, there are fluctuations according 
to the individual condition, which include benign prostatic 
hyperplasia, prostatitis, and other nonmalignant conditions. 
Clinical staging determination based on digital rectal examina-
tion is imprecise for the evaluation of extraprostatic disease. 
However, magnetic resonance imaging avoids inaccurate 
classifications of prostate cancer. Nevertheless, the accurate 
determination of clinical staging in the disease still has un-
resolved issues. In addition, the preoperative Gleason score 
does not represent the postoperative Gleason score in the RP 
specimens.
 Because of these limitations, several multivariate risk as-
sessment tools have been developed. One well-known risk 
assessment tool is the Kattan nomogram [15]. This tool uses 
the PSA, Gleason score, clinical stage of the disease, and ad-
ditional prostate biopsy information. Recently, Cooperberg 
et al. [16] developed another high-risk prostate cancer defi-
nition: the Cancer of the Prostate Risk Assessment (CAPRA) 
score. They added secondary parameters, including prostate 
biopsy profiles and age of the patient to the existing basic pa-
rameters. The CAPRA score ranges from 0 to 10, and a CAPRA 
score of 6–10 represents high-risk prostate cancer. This tool 
was recently updated because the CAPRA postsurgical score 
(CAPSA-S) and the postoperative pathologic results can be 
used to predict BCR after RP [17]. A consensus on the defini-
tion of high-risk prostate cancer as a worldwide standard is 
an urgent priority even though various tools based on clinic-
pathological information have been validated as useful in 
prostate cancer risk stratification.
RADICAL PROSTATECTOMY FOR HIGH-
RISK PROSTATE CANCER
RP is considered the treatment of choice in low- and interme-
diate-risk prostate cancer patients. However, the role of RP in 
high-risk prostate cancer remains controversial. Not very long 
ago, many urologists agreed that RP was not a suitable treat-
ment option for high-risk prostate cancer patients because 
they accepted that the BCR rate and systemic progression rate 
after RP was significantly higher than that in other risk pros-
tate cancer patients [18]. However, several recent studies of 
high-risk prostate cancer have presented another view [19-24]. 
 Recently, Johns Hopkins medical institutions reported their 
experiences of RP outcomes in high-risk prostate cancer pa-
tients. Loeb et al. [25] reported that a 10-year BCR rate was 
32% with a 16% rate of metastasis and a 92% cancer specific 
survival (CSS) rate in high-risk prostate cancer patients who 
underwent RP. Spahn et al. [26] reported that the 5- and 
Table 1. Definition of high-risk prostate cancer
Investigator Definition
D'Amico et al. [12] PSA≥20 ng/mL or GS 8–10 or clinical stage≥T2c 
American Urologic Association [2] PSA≥20 ng/mL or GS 8–10 or clinical stage≥T2c 
European Association of Urology [1] PSA≥20 ng/mL or GS 8–10 or clinical stage≥T3a 
National Comprehensive Cancer Network 
[13]
PSA≥20 ng/mL or GS 8–10 or clinical stage≥T33 or any two of following criteria: T2b/c, GS 7, PSA 10–20 
ng/mL
Radiation Therapy Oncology Group [14] PSA 20–100 ng/mL, GS 8–10, and any clinical stage or clinical stage≥ T2c or PSA< 100 ng/mL and GS 8–10 
PSA, prostate-specific antigen; GS, Gleason score.




10-year CSS was 89.8% and 84.5%, respectively, in 712 men 
with high-risk disease with preoperative PSA over 20 ng/mL. 
Zwergel et al. [27] also reported that the 5-, 10-, and 15-year 
CSS was 93%, 83%, and 71%, respectively, using 275 high-risk 
prostate cancer patients at a median of 42 months follow-up. 
They also used a cohort study with prostate cancer patients 
who had a preoperative PSA over 20 ng/mL. In cases of pa-
tients with prostate cancer in clinical stage T3a, Hsu et al. [28] 
reported the oncological outcomes of 200 men with initial 
clinical stage T3a disease who were treated by RP. At 10 years, 
the progression-free survival (PFS), CSS, and overall survival 
(OS) were 85.4%, 91.6%, and 77%, respectively. Long-term 
follow-up data was reported by Eggener et al. [29] for patients 
who had a high preoperative Gleason score between 8 and 
10. They reported that the 10- and 15-year CSS was 72% and 
89%, respectively. Boorjian et al. [30] reported that the 7-year 
CSS rate was 91% in a series of 584 men treated with RP with 
a Gleason score between 8 and 10. 
 Similarly, several studies supported the finding that RP 
could result in long term PFS and CSS despite the high rate of 
BCR in comparison with low- and intermediate-risk prostate 
cancer patients. RP had a potential role in men with high-risk 
prostate cancer. However, we should remember that these ob-
servations were influenced by pathological down staging and 
downgrading in comparison with clinical staging and grading 
[31-33]. Many patients who had clinically suspected high-risk 
prostate cancer were later revealed as pathologically favorable 
prostate cancer patients. According to several studies, about 
20 to 30% of patients were pathologically down-staged to pT2 
at the time of surgery. The proportion of patients who were 
cured by RP alone was quite low in comparison to low- and 
intermediate-risk prostate cancer patients. We found that 
many patients who showed long-term PFS and CSS received 
adjuvant therapy including RT and HT. Thus, no one can ar-
gue that patients who had pathologically unfavorable disease 
had a higher risk of BCR and disease progression in compari-
son with other patients. 
ADJUVANT RADIOTHERAPY IN HIGH-
RISK PROSTATE CANCER PATIENTS
An important issue in treatment after RP is how to control 
the oncological outcomes of pathological high-risk prostate 
cancer patients. A high BCR rate after RP in high-risk prostate 
cancer was reported in several studies, especially in patients 
with positive surgical margins, extraprostatic extensions, and 
seminal vesicle invasion. In these patients, the issue was 
whether adjuvant radiotherapy (ART) could improve the on-
cological outcomes or not. 
 Recently, three randomized trials were reported [34-36]: 
the European Organisation for Research and Treatment of 
Cancer (EORTC) trial 22911, the Southwest Oncology Group 
(SWOG) trial 87-94, and the ARO 96-02/AUO AP 09/95. All 
three trials demonstrated improvement in BCR-free survival 
and excellent local control. However, only one trial, SWOG 
trial 87-94, noted a significant improvement in overall surviv-
al. The EORTC trial 22911 reported that ART improved BCR-
free survival only. However, there were no benefits in PFS and 
overall survival reported in this trial [37]. Furthermore, patient 
selection bias was observed in these trials. Not all patients in 
the SWOG trial had a complete record of preoperative PSA. 
In addition, the effects of surgical margin status were not suf-
ficient to explain the results of the SWOG trial. In the EORTC 
trial 22911 and the ARO trial, researchers analyzed the effects 
of surgical margin status and concluded that the benefit of 
BCR-free survival may be limited to patients with positive sur-
gical margins. Therefore, ART after RP in pathological high-
risk prostate cancer patients is not an accepted treatment 
despite these excellent trial findings. Swindle et al. [38] con-
cluded that ART might be over-treated in 50% of patients who 
could have been cured by RP alone. Most importantly, high-
risk prostate cancer patients with pathologically localized 
disease and positive surgical margins might be cured with RP 
alone and thus not require ART. However, patients with nega-
tive surgical margins could have a poor outcome in high-risk 
prostate cancer. In other words, the prediction of oncologi-
cal outcomes after RP in high-risk prostate cancer patients 
is difficult. Therefore, close surveillance is required for these 
patients if the urologist selects RP as the initial modality for 
prostate cancer treatment. 
ADJUVANT HORMONE THERAPY IN 
HIGH-RISK PROSTATE CANCER PA-
TIENTS
HT has also been investigated as an adjuvant therapy to RP in 
high-risk prostate cancer patients even though few random-
ized trials are available. Messing et al. [39] showed a potential 
benefit to early hormonal therapy following RP. At a follow-up 
of 11 years, a significant improvement was exhibited in OS, 
CSS, and PFS in the adjuvant HT group. However, these re-
sults were observed in a small trial of patients who were posi-
tive for lymph node. In cases of patients with negative lymph 
node, this advantage was not demonstrated. In a randomized 
study with flutamide in 309 patients, Wirth et al. [40] also 
reported an improvement in PFS with immediate androgen 




deprivation therapy (ADT). Adjuvant flutamide treatment 
delayed biochemical progression significantly; however, no 
difference was found in OS or CSS at a follow-up period of 6.1 
years. However, in a randomized clinical trial McLeod et al. 
[41] concluded that patients with high-risk locally advanced 
disease might benefit from adjuvant ADT. Unfortunately, at a 
follow-up of 6 years, no improvement in OS was reported for 
the pT3. Recently, Siddiqui et al. [42] analyzed 191 patients 
with seminal vesicle invasion who received adjuvant HT. At 
a follow-up of 10 years, they experienced an improvement 
in BCR-free survival and CSS in comparison to patients who 
did not receive adjuvant HT. However, they also did not show 
a significant improvement in OS. Therefore, the advantages 
of adjuvant hormonal therapy after RP are debatable. The re-
sults of the aforementioned studies indicated that except for 
patients with positive lymph nodes, the role of adjuvant HT 
after RP remains unclear and is not recommended. Definitive 
results from a large randomized trial are warranted in order 
to define the role of adjuvant HT in high-risk prostate cancer.
RADICAL PROSTATECTOMY AND RA-
DIOTHERAPY: WHICH IS THE SUPERIOR 
TREATMENT? 
A comparison of RP and RT is difficult because there are no 
compared prospective trials and these two treatments have 
different PSA nadir standards. Almost all results were from 
large retrospective and case-matched studies. Cooperberg 
et al. [43] compared the risk-adjusted mortality in 7,538 men 
treated by RP, RT, or ADT. The study showed that higher-risk 
patients had better CSS following surgery in comparison with 
other treatments. In a retrospective observational study, 
Abdollah et al. [44] reviewed the comparative treatment out-
comes of clinically localized prostate cancer. They found that 
disease-specific mortality was lower in men aged < 69 years 
with high-risk disease when they choose RP. However, there 
was no significant difference between RP and RT in patients 
over 70 years. Arcangeli et al. [45]’s retrospective study used 
a small cohort to analyze patients who underwent RP or RT. 
They showed a significantly better outcome after RT than af-
ter RP in patients with high-risk prostate cancer. Tewari et al. 
[46] compared 453 high-risk prostate cancer patients treated 
by RP, RT, or observation. They concluded that RP was supe-
rior to RT in OS, but it was not significant in CSS.
 In contrast, Westover et al. [47] compared long-term sur-
vival in high-risk men treated by either RP or RT. They found 
that there was no significant difference in disease-specific 
mortality between the two treatment modalities. Boorjian et 
al. [48] compared patients with high-risk prostate cancer un-
dergoing RP (n = 1,238) or RT with ADT (n = 344) or without 
ADT (n = 265) from 1988 until 2004. They showed that the 10-
year cancer-specific survival rates were 92%, 92%, and 88% 
after RP, RT plus ADT, and RT, respectively, and they were 
not significantly different. Systemic PFS also did not signifi-
cantly differ between the treatment modalities. However, the 
OS was greater in men who underwent RP than those who 
had RT ± HT. Recently, Parikh and Sher [49] published an 
interesting article comparing the quality-adjusted life expec-
tancy (QALE) between men with high-risk prostate cancer 
who received RT+HT versus RP+RT versus a hypothetical 
trimodality therapy (RP+RT+HT). They reported that RT+HT 
resulted in a higher QALE compared with RP+RT over a wide 
range of assumptions, which nearly always resulted in an in-
crease of > 1 quality-adjusted life year with outcomes highly 
sensitive to the risk of increased all-cause mortality from HT; 
RP+RT+HT was typically superior to RT+HT. They concluded 
that high-risk prostate cancer patients who underwent RT+HT 
were superior to RP+RT, and the result was sensitive to the risk 
of all-cause mortality from HT. Moreover, trimodality therapy 
may offer local and distant control benefits that lead to opti-
mal outcomes in a meaningful population of men. 
 The results shown in the relevant literature indicate that it 
is unclear whether RP or RT is superior for high-risk prostate 
cancer. Even though some oncological outcomes demon-
strated the superiority of RP, it must be taken into account 
that several experienced urologists concluded that there 
were no significant differences in oncological outcomes be-
tween RP and RT. Although these large retrospective studies 
provided some information, for the ideal comparison of RP 
and RT in high-risk prostate cancer, we need more results 
from high-level studies in prospective randomized trial set-
tings. Moreover, with regard to prospective randomized trials, 
a number of issues must be resolved when comparing RP 
and RT; the main problem is the “Will Rogers phenomenon.” 
This term refers to the improvement in survival rates in stage-
specific prognosis caused by changing the criteria for assign-
ing patients to the various stages of a disease, even though the 
outcome of the individual patients does not change. 
 To compare the oncological outcomes between RP and RT 
in high-risk prostate cancer, we included patients in a cohort 
study using a clinical risk classification system. However, in 
patients who underwent RP, we identified their pathologic 
staging and determined whether the patient was overestimat-
ed or not in the risk assessment for prostate cancer. However, 
in high-risk prostate cancer patients who underwent RT, we 
could not ascertain the exact pathologic staging. Therefore, 




it is impossible to identify the actual position of RT in these 
patients. It was difficult to compare patients who underwent 
RT with those who did not undergo RP, even in a prospective 
randomized trial. There was no way to identify accurately the 
pathologic status of patients who underwent RP. Consequent-
ly, we classified them as clinically high-risk prostate cancer 
in this study. However, in reality, these same patients would 
not be classified as having pathologically high-risk prostate 
cancer. Therefore, the question of which treatment is better 
for high-risk prostate cancer patients remains unresolved.
CONCLUSION
Presently, RP is regarded as the first step of treatment for high-
risk prostate cancer patients, on a selective basis. In some 
high-risk prostate cancer patients, RP is a one-step modality 
for a cure, with excellent oncological prognosis. Nevertheless, 
a substantial proportion of prostate cancer patients need 
adjuvant therapy after RP. In these patients, urologists should 
utilize a tailored approach with RT or HT. Therefore, before 
utilizing RP, urologists should inform patients about the pos-
sibility of surgical complications caused by the wide excision 
created during surgery and the need of adjuvant therapy, 
including RT and HT. The main goal of treatment for high-
risk prostate cancer is the improved CSS, not BCR. Therefore, 
in patients who are willing to undergo radical therapies in 
pursuit of a cure, I agree that RP could be an attractive thera-
peutic option for high-risk prostate cancer. However, further 
studies with randomized controlled trials comparing RP and 
RT are necessary for urologists and their patients to be better 
informed.
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